Leukotriene B4 receptor 1 is differentially expressed on peripheral T cells of steroid-sensitive and -resistant asthmatics

Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology (Impact Factor: 2.6). 01/2014; 112(3). DOI: 10.1016/j.anai.2013.12.006
Source: PubMed


Numbers of CD8(+) T cells expressing the leukotriene B4 (LTB4) receptor, BLT1, have been correlated with asthma severity.
To examine the activation and numbers of BLT1-expressing peripheral blood CD4(+) and CD8(+) T cells from patients with steroid-sensitive (SS) and steroid-resistant (SR) asthma.
CD4(+) and CD8(+) T cells isolated from peripheral blood of healthy human subjects and patients with SS and SR asthma were stimulated in culture with anti-CD3/anti-CD28 followed by analysis of BLT1 surface expression and cytokine production. Activation of CD8(+) T cells after ligation of BLT1 by LTB4 was monitored by changes in intracellular Ca(2+) concentrations.
The number of BLT1-expressing cells was larger in patients with asthma than in controls and larger on activated CD8(+) than on CD4(+) T cells. Addition of LTB4 to activated CD8(+) T cells resulted in increases in intracellular Ca(2+) concentrations. Expansion of activated CD4(+) T cells, unlike CD8(+) T cells, was significantly decreased in the presence of corticosteroid. In patients with SS asthma, numbers of BLT1-expressing CD8(+) T cells were lower in the presence of corticosteroid, unlike in those with SR asthma in whom cell expansion was maintained. Levels of interleukin-13 were highest in cultured CD8(+) T cells, whereas interleukin-10 levels were higher in CD4(+) T cells from controls and patients with SS asthma. Interferon-γ levels were lowest in patients with SR asthma.
Differences in BLT1 expression, steroid sensitivity, and cytokine production were demonstrated in T lymphocytes from patients with SS and SR asthma. The LTB4-BLT1 pathway in CD8(+) cells may play an important role in asthma and serve as an important target in the treatment of patients with SR asthma.

6 Reads
  • Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 03/2015; 114(3):164-5. DOI:10.1016/j.anai.2014.11.017 · 2.60 Impact Factor
  • Journal of Allergy and Clinical Immunology 03/2015; 135(5). DOI:10.1016/j.jaci.2015.01.032 · 11.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly named Churg–Strauss syndrome, is an antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) occurring in asthmatic patients. EGPA prognosis has been revolutionized by the use of glucocorticoids and immunosuppressant(s). Following recent advances in the management of AAV, eosinophilic disorders and asthma, several novel immunomodulatory drugs and biotherapies were or are currently being evaluated for EGPA.Areas covered: Herein, based on pathogenesis and clinical characteristics, we review EGPA standard of care; the different therapeutic options available; and address forthcoming therapeutic perspectives.Expert opinion: EGPA prognosis is very good, with overall 5-year survival now reaching 90%. Like other systemic necrotizing vasculitides, EGPA treatment comprises induction and maintenance phases. Glucocorticoids are the cornerstone of induction therapy. Cyclophosphamide should be added when the prognosis is poor (as defined by the prognostic Five-Factor Score). Immunosuppressants (e.g., mainly azathioprine or methotrexate) are prescribed for an as yet undefined time (usually 18 – 24 months) following remission-induction. Chronic asthma, peripheral neuropathy, heart involvement and glucocorticoid-dependence are challenging clinical situations. Biotherapies (e.g., omalizumab, rituximab and mepolizumab) hold promise for EGPA treatment. Whether patients might benefit from distinct therapeutic strategies depending on their ANCA status (e.g., rituximab for ANCA-positive or mepolizumab for ANCA-negative patients) requires further investigation.
    Expert Opinion on Orphan Drugs 04/2015; 3(5). DOI:10.1517/21678707.2015.1025748 · 0.53 Impact Factor
Show more